EDU 44 - ASTRO/KCA Joint Session: Stereotactic Radiotherapy and Renal Cell Cancer, Overcoming Radioresistance and the Resistance to Radiate
MODERATOR(S)
Shankar Siva, PhD, MBBS, FRANZCR - Peter MacCallum Cancer Centre
session DESCRIPTION
This session brings together an international panel and multidisciplinary expertise to discuss the emerging role of SABR to the primary in renal cell carcinoma (RCC). The session will focus on patients who have localised disease treated for cure, and to a lesser extent the role of SABR to patients with oligometastatic RCC treated with "definitive intent." An overview on the historical concept of radioresistance in RCC and the rationale for SABR will be introduced. Building on this, relevant epidemiology, comparative effectiveness, and health services data will be reviewed. Indications for primary renal SABR will be discussed within the hierarchy of alternative ablative/extirpative techniques. An overview of technical considerations and response assessment will be provided, with a focus on different treatment platforms, immobilization techniques, motion management strategies, dose prescriptions and organ at risk constraints. These will include discussion of limitations and common practical barriers faced in the delivery of SABR to primary RCC. Challenging scenarios such as the presence of a single kidney, IVC thrombus, and large/anatomically challenging tumors will be discussed. Various clinical considerations for SABR within metastatic RCC will be explored from a medical oncology and radiation oncology perspective, including its application for oligometastatic targets and the use of SABR to the primary as an alternative to cytoreductive nephrectomy. Finally, the early clinical experience of the MR-Linac platform for primary RCC will be shared.
learning objectives
- Discuss the evidence to support SABR as a modality that overcomes perceived radioresistance of primary RCC.
- Review practical and technical considerations in the treatment of and surveillance following SABR for primary RCC.
- Discuss the role of novel systemic therapy, surgery and radiotherapy for oligometastatic RCC.
Credits
| AMA PRA Category 1 Credits: | 1.50 |
Presentations
-
03:40pm - 04:00pm PT
Case Discussions
Speaker: Chad Tang, MD - MD Anderson Cancer Center, Houston -
03:14pm - 03:27pm PT
Multidisciplinary Management from Urology
Speaker: Brian Shuch, MD - University of California Los Angelos, Los Angelos -
02:30pm - 04:00pm PT
ASTRO/KCA Joint Session: Stereotactic Radiotherapy and Renal Cell Cancer, Overcoming Radioresistance and the Resistance to Radiate
Speaker: Shankar Siva, PhD, MBBS, FRANZCR - Peter MacCallum Cancer Centre, Parkville -
02:30pm - 02:35pm PT
Introductions
Speaker: Shankar Siva, PhD, MBBS, FRANZCR - Peter MacCallum Cancer Centre, Parkville -
02:35pm - 02:48pm PT
A Primer on Radiotherapy in Renal Cancer
Speaker: Nicholas Zaorsky, MD, MS - University Hospitals, Cleveland -
02:48pm - 03:01pm PT
Technical Considerations, Response Assessment and Challenging Cases in Primary Renal SABR
Speaker: Anna Bruynzeel, MD, PhD - VU University Medical Center, Amsterdam -
03:01pm - 03:14pm PT
Multidisciplinary Management from Medical Oncology
Speaker: Rana Mckay, MD - University of California San Diego, San Diego -
03:14pm - 03:27pm PT
Multidisciplinary Management from Urology
Speaker: Brian Shuch, MD - University of California Los Angelos, Los Angelos -
03:27pm - 03:40pm PT
From the IROCK Experience in Primary RCC to Expanding the Role in Oligometastatic RCC
Speaker: Raquibul Hannan, MD, PhD - UT Southwestern Medical Center, Dallas -
03:48pm - 04:00pm PT
Questions and Answers
Speaker: Shankar Siva, PhD, MBBS, FRANZCR - Peter MacCallum Cancer Centre, Parkville